Altis Labs, a Toronto, Canada-based computational imaging company, raised US$6M in Seed funding.
The round was led by Benchstrength and Debiopharm Innovation Fund, with participation from strategic angels including Doug Foster, the former CEO of digital health company Verana Health, and Richard Gliklich, MD, the founder and CEO of real-world data company OM1.
The company intends to use the funds to scale the development of Nota, Altis’ AI-powered imaging biomarker platform, across solid tumor types and therapeutic areas.
Led by Felix Baldauf-Lenschen, CEO, Altis Labs is a computational imaging company focused on precision medicine. Biopharma companies use its software platform, Nota, to accelerate and de-risk all stages of clinical development. Trained on over 182 million real-world images with associated diagnostics, treatment information, and outcomes, Nota predicts clinically outcomes from baseline and follow-up scans to accurately stratify patients and quantify treatment effect.
Altis hosts proprietary prognostic models in the Nota cloud platform for biopharma R&D teams to automatically analyze clinical trial imaging data. Model predictions allow researchers to more accurately stratify patients at baseline and measure treatment effect across subpopulations. These insights help sponsors generate high quality evidence earlier in clinical development to increase success rates in late-stage trials and inform critical R&D decisions spanning go/no-go, trial design, reimbursement strategy, and revivals of shelved assets.
FinSMEs
21/06/2023